Cathelicidin (LL-37) vs Indolicidin — mechanism, half-life, dosing, and research status compared. Which is right for your protocol?
LL-37 is the sole human cathelicidin antimicrobial peptide, derived by proteolytic cleavage of the 18 kDa precursor hCAP18 (encoded by the CAMP gene). It is produced by neutrophils, epithelial cells of the skin, gut, and airways, and mast cells....
Calculate Cathelicidin (LL-37) dose →Indolicidin is a 13-residue, tryptophan-rich antimicrobial peptide from bovine neutrophil granules. It is the smallest naturally occurring AMP with broad-spectrum activity....
Calculate Indolicidin dose →| Parameter | Cathelicidin (LL-37) | Indolicidin |
|---|---|---|
| Category | Antimicrobial Peptide | Antimicrobial Peptide |
| Research | Clinical Research | Phase II (completed) |
| Half-Life | < 10 min (plasma) | Minutes to hours |
| Typical Dose | Research: 1-100 ug/mL (topical) | N/A |
| Frequency | Varies by application | N/A |
| Route | Endogenous; topical/inhalation (research) | Topical |
| FDA Status | No approval (clinical trials ongoing) | Not approved |
Use ASCEND's free reconstitution calculator to get exact syringe draw amounts for your vial.
For research use only. Not medical advice. ASCEND does not conduct or endorse any specific research protocol. Always consult relevant scientific literature and regulatory guidelines.